Floatz logo

Bms-907351

Metastatic Kidney Carcinoma

Fondazione Policlinico Universitario Agostino Gemelli IRCCSPhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

41 Active assets in the Metastatic Kidney Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BBB
Ipilimumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Pembrolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
ROPIVACAINE
Wake Forest University Health Sciences
Phase 3B
LENVATINIB
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3B

View all 50 →

Same molecule, other indications

Bms-907351 is also rated in:

castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
differentiated thyroid carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →